AppliedXL provides an AI-driven platform that continuously monitors clinical, regulatory, and scientific signals to identify execution risks and disruptions in pivotal Phase II/III and III oncology trials across major global regions. The platform delivers contextual, analyst-grade insights with source-backed explanations, enabling biopharma teams, investors, and contract research organizations to anticipate trial outcomes and adjust strategies in real time.